Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telomelysin with Keytruda and SBRT in advanced HNSCC
NCT04685499Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of suratadenoturev in head and neck squamous cell carcinoma (HNSCC), sponsored by Weill Cornell Medicine. Started May 2021; status: terminated.
02
Drugs
suratadenoturev
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04685499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685499.